Oppenheimer Maintains Perform on Acadia Pharmaceuticals, Lowers Price Target to $21
Benzinga Newsdesk 10 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Oppenheimer analyst Matthew Hershenhorn maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Perform and lowers the price target from $23 to $21.
Oppenheimer analyst Matthew Hershenhorn maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Perform and lowers the price target from $23 to $21.
